Avistone Biotechnology

Privately held: no public share price

Assets

(3 total)
3Total Assets
0Approved
2Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
Showing 3 of 3 assets
Target & Modality
Phase 3
EGFRSmall molecule
Non-Small Cell Lung Cancer
Phase 3
METSmall molecule
Non-Small Cell Lung CancerGlioma
Non-Small Cell Lung Cancer with MET Exon 14 Skipping
Phase 1/2
EGFRSmall molecule
Non-Small Cell Lung Cancer

Upcoming events

(5 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (2)
November 2026 (1)
AndamertinibPhase 2Non-Small-Cell Lung Cancer
Est. primary completion 2026-11 · NCT07336732 · CT.gov ↗
What to watch
December 2026 (1)
Andamertinib + VebreltinibPhase 1/2Non-Small-Cell Lung Cancer
Est. primary completion 2026-12-31 · NCT06343064 · CT.gov ↗
What to watch
2027 (1)
December 2027 (1)
Andamertinib + VebreltinibPhase 3Non-Small-Cell Lung Cancer
Est. primary completion 2027-12-31 · NCT06970782 · CT.gov ↗
What to watch
2028 (1)
June 2028 (1)
AndamertinibPhase 3Non-Small-Cell Lung Cancer
Est. primary completion 2028-06-30 · NCT06281964 · CT.gov ↗
What to watch
2029 (1)
June 2029 (1)
ANS02Phase 1/2Non-Small Cell Lung Cancer
Est. primary completion 2029-06-30 · NCT07538804 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.